| Market Cap | 40.15M | P/E | - | EPS this Y | 45.60% | Ern Qtrly Grth | - |
| Income | -106M | Forward P/E | -0.72 | EPS next Y | 19.70% | 50D Avg Chg | -20.00% |
| Sales | 16.76M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -48.00% |
| Dividend | N/A | Price/Book | 0.54 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 3.00 | Quick Ratio | 2.37 | Shares Outstanding | 39.76M | 52W Low Chg | 65.00% |
| Insider Own | 15.52% | ROA | -40.88% | Shares Float | 18.21M | Beta | - |
| Inst Own | 76.92% | ROE | -115.52% | Shares Shorted/Prior | 115.50K/241.92K | Price | 1.00 |
| Gross Margin | -5.52% | Profit Margin | - | Avg. Volume | 978,716 | Target Price | 1.70 |
| Oper. Margin | -578.64% | Earnings Date | Nov 10 | Volume | 56,424 | Change | -0.50% |
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut. As of March 21, 2023, IsoPlexis Corporation operates as a subsidiary of Berkeley Lights, Inc.
| Morgan Stanley | Equal-Weight | Jan 5, 23 |
| SVB Leerink | Market Perform | Dec 22, 22 |
| SVB Leerink | Market Perform | Nov 11, 22 |
| Morgan Stanley | Equal-Weight | Aug 11, 22 |
| SVB Leerink | Market Perform | Aug 11, 22 |
| Morgan Stanley | Overweight | May 12, 22 |
| SVB Leerink | Outperform | May 12, 22 |
| Morgan Stanley | Overweight | Feb 15, 22 |
| SVB Leerink | Outperform | Jan 27, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SHAMIR NACHUM | Director Director | Aug 30 | Buy | 1.92 | 50,253 | 96,486 | 50,253 | 09/01/22 |
| Strahley John | Chief Financial Offi.. Chief Financial Officer | Aug 25 | Buy | 2.00 | 10,000 | 20,000 | 65,000 | 08/29/22 |
| Mackay Sean | Chief Executive Offi.. Chief Executive Officer | Aug 25 | Buy | 1.99 | 15,000 | 29,850 | 914,366 | 08/29/22 |
| Rew Richard W. II | SVP, GC and Secretar.. SVP, GC and Secretary | Aug 25 | Buy | 1.99 | 20,000 | 39,800 | 20,000 | 08/29/22 |
| Mackay Sean | Chief Executive Offi.. Chief Executive Officer | Aug 19 | Option | 0.28 | 100,166 | 28,046 | 899,366 | 08/22/22 |
| Strahley John | Chief Financial Offi.. Chief Financial Officer | Aug 17 | Option | 1.0275 | 15,000 | 15,413 | 55,000 | 08/18/22 |
| Strahley John | Chief Financial Offi.. Chief Financial Officer | Apr 22 | Option | 1.0275 | 12,500 | 12,844 | 25,000 | 04/25/22 |
| PERCEPTIVE ADVISORS LLC | 10% Owner 10% Owner | Oct 12 | Buy | 15 | 850,000 | 12,750,000 | 3,554,587 | 10/14/21 |